The Academic Minute: Why Parkinson’s Drug Improves, then Diminishes Quality of Life

Treating Parkinson’s disease is never an easy prospect.

Amal Alachkar, associate professor of teaching pharmaceutical sciences at the University of California, Irvine, breaks down the issues with one method of treatment.

Dr. Amal Alachkar is a Syrian-American neuroscientist and pharmacologist whose research focuses on dissecting the genetic, molecular, and chemical mechanisms underlying cognitive and emotional functions. She is particularly interested in understanding how the dysregulations of particular brain circuits lead to neurological and psychiatric disorders such as Parkinson’s disease, schizophrenia, autism, and depression. Her research aims to identify novel therapeutic strategies and molecular targets for the treatment of the neurological and psychiatric disorders.

To read or listen to the entire episode, visit theacademicminute.org.

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Subscribe To Our Newsletter

Get updates From the UCI School of Pharmacy and Pharmaceutical Sciences

More To Explore

0 Shares
Share
Tweet
Share